NİHAN ÜNÜBOL, NEVAL YURTTUTAN UYAR, MELTEM AYAS
The Journal of European Internal Medicine Professionals - 2025;3(1):35-40
Background: The rate of fungal infection has increased due to advances in medical and surgical treatment. Recently, Candidiasis has become one of the major fungal infections among hospitalized patients. While various Candida species may cause the same clinical manifestations, they may also have different antifungal susceptibility patterns. The aim of this study was to determine the distribution and antifungal susceptibilities of Candida species isolated from various clinical specimens. Methods: Various Candida species were isolated from different clinical samples sent to Acıbadem Labmed Medical Laboratory between 2015 and 2023. Antibiotic susceptibility studies of isolated Candida species were performed with Yeast one kit (Thermo Scientific™, USA) and the results were evaluated according to CLSI data. Results: From 922 samples, most common species isolated was C. albicans (30.9%), followed by C. parapsilosis, C. glabrata, C. tropicalis and C. krusei. Candida species were sensitive to Fluconazole 76.2%, Itraconazole 64.1%, Voriconazole 93.1%, Anidulafungin 99.1%, Micafungin 99.1%, Caspofungin 98.9% and Flucytosine 92.6%. The antibiotic resistance rates of Candida species were Fluconazole 15.5%, Itraconazole 8.1%, Voriconazole 4.5%, Anidulafungin 0.7%, Micafungin 0.2%, Caspofungin 0.8% and Flucytosine 1.9%. Conclusion: Speciation of Candida and antifungal susceptibility testing should be done routinely to prevent therapeutic failures.
